XVIVO Perfusion: Q2, XVIVO delivers improved growth with a solid outlook - Redeye

The Thoracic business delivers CER organic growth of 82% with improved gross margins with significant US support. Both the Thoracic and the Abdominal business (underlying organic Q2 growth of 126%) is likely to improve in Europe, where some countries suffer from more extensive lockdowns. In 2021, we can expect more support from UK sales and a US launch of Kidney Assist Transport. We expect a positive reaction on the back of Q2 and improved structural support ahead.

https://www.redeye.se/research/816867/xvivo-perfusion-q2-xvivo-delivers-improved-growth-with-a-solid-outlook?utm_source=finwire&utm_medium=RSS